Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 13/20 | 0.68 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.61 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.61 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.59 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.59 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.59 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.59 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.59 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.58 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16805401 | 1.00 | P2RY2 (0.68) | P2RY2P2RY6P2RY4ENPP1P2RY1 | |
| SCHEMBL624932 | 1.00 | P2RY2 (0.68) | P2RY2P2RY6P2RY4ENPP1P2RY1 | |
| SCHEMBL18609299 | 1.00 | P2RY2 (0.68) | P2RY2P2RY6P2RY4ENPP1P2RY1 | |
| SCHEMBL17210998 | 1.00 | P2RY2 (0.68) | P2RY2P2RY6P2RY4ENPP1P2RY1 | |
| SCHEMBL14661260 | 0.98 | P2RY2 (0.65) | P2RY2P2RY6P2RY4ENPP1P2RY1 | |
| SCHEMBL14661258 | 0.98 | P2RY2 (0.65) | P2RY2P2RY6P2RY4ENPP1P2RY1 | |
| SCHEMBL16805307 | 0.92 | P2RY2 (0.57) | P2RY2P2RY6P2RY4ENPP1P2RY1 | |
| SCHEMBL903054 | 0.90 | FBP1 (0.57) | P2RY2P2RY6P2RY4P2RY1P2RY11 | |
| SCHEMBL17809090 | 0.90 | FBP1 (0.57) | P2RY2P2RY6P2RY4P2RY1P2RY11 | |
| SCHEMBL3504116 | 0.90 | FBP1 (0.57) | P2RY2P2RY6P2RY4P2RY1P2RY11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1046 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161488-A1 | THERAPEUTIC mRNA | THE UNIVERSITY OF MELBOURNE (AU) | 2025-05-22 | — | — | US | claimed |
| WO-2025061107-A1 | COMPOSITION COMPRISING MRNA ENCODING INFLUENZA VIRUS HA PROTEIN AND USE THEREOF | ARGORNA PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | WO | claimed |
| CN-119679931-A | MRNA composition containing coded influenza virus HA protein and application thereof | 阿格纳生物制药有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-119375375-A | Method for detecting nucleotide, cap analogue and nucleic acid in vitro transcription product | 楷拓生物科技(苏州)有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-119345129-A | Cyclic IL-10mRNA nano preparation and preparation method and application thereof | 环信生物科技(泰州)有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-119264229-A | Vaccine and composition based on S protein of different omnikom variants of SARS-CoV-2 | 阿格纳生物制药有限公司 | 2025-01-07 | — | — | CN | claimed |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | TRANSLATE BIO INC (US) | 2024-12-19 | — | — | US | claimed |
| US-20240350619-A1 | VACCINES AND COMPOSITIONS BASED ON SARS-COV-2 S PROTEIN | GUANGZHOU RIBOBIO CO., LTD. (CN) | 2024-10-24 | — | — | US | claimed |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | TRANSLATE BIO, INC. (US) | 2024-06-04 | — | — | US | claimed |
| CN-113925975-B | Preparation method of p53 and UTX messenger RNA nanoparticles and application of messenger RNA | 杭州师范大学 | 2024-05-28 | — | — | CN | claimed |
| US-20160145346-A1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2016-05-26 | — | — | US | claimed |
| EP-2968586-A2 | CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES | Shire Human Genetic Therapies, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014153052-A9 | CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2015-08-06 | — | — | WO | claimed |
| WO-2014153052-A2 | CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20130195867-A1 | RNA-CODED ANTIBODY | CUREVAC GMBH (DE) | 2013-08-01 | — | — | US | claimed |
| US-20100189729-A1 | RNA-CODED ANTIBODY | CURVAC GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| EP-2101823-A2 | RNA-CODED ANTIBODY | Curevac GmbH (DE) | 2009-09-23 | — | — | EP | claimed |
| WO-2008083949-A2 | RNA-CODED ANTIBODY | CUREVAC GMBH (DE) | 2008-07-17 | — | — | WO | claimed |
| EP-1848827-A2 | METHODS AND COMPOSITIONS FOR TAGGING AND IDENTIFYING POLYNUCLEOTIDES | Compass Genetics, Llc (US) | 2007-10-31 | — | — | EP | claimed |
| WO-2006086210-A2 | METHODS AND COMPOSITIONS FOR TAGGING AND IDENTIFYING POLYNUCLEOTIDES | COMPASS GENETICS, LLC (US) | 2006-08-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145346-A1 | RNA-CODED ANTIBODY | TRDMT1, NSUN3, POLRMT | P2RY2 3997/4885P2RY6 3779/4885P2RY4 3748/4885 |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | NSUN3, RNMT, TRDMT1 | P2RY2 3741/4885P2RY6 3298/4885P2RY4 4107/4885 |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | NSUN3, RNMT, TRDMT1 | P2RY2 3741/4885P2RY6 3298/4885P2RY4 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.